Insulin resistance is an underlying mechanism of impaired
glucose metabolism during nilotinib therapy

J 2018

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

RÁČIL, Zdeněk, Eva KORIŤÁKOVÁ, Tomasz SACHA, Hana KLAMOVA, Petra BELOHLAVKOVA et. al.

Basic information

Original name

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

Authors

RÁČIL, Zdeněk (203 Czech Republic, guarantor, belonging to the institution), Eva KORIŤÁKOVÁ (203 Czech Republic, belonging to the institution), Tomasz SACHA (616 Poland), Hana KLAMOVA (203 Czech Republic), Petra BELOHLAVKOVA (203 Czech Republic), Edgar FABER (203 Czech Republic), Delphine REA (250 France), Ludmila MALASKOVA (203 Czech Republic), Jiřina PROCHÁZKOVÁ (203 Czech Republic), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Jaroslava VOGLOVA (203 Czech Republic), Joanna WACLAW (616 Poland), Petr CETKOVSKY (203 Czech Republic), Pavel ZAK (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

American Journal of Hematology, Hoboken, John Wiley & Sons, 2018, 0361-8609

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 6.137

RIV identification code

RIV/00216224:14110/18:00104917

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/ajh.25232

UT WoS

000447533300007

Keywords in English

nilotinib therapy

Abstract

V originále

Impaired glucose metabolism (IGM) with hyperglycemia represents one of the most frequently observed adverse events (AE) during nilotinib therapy of chronic myeloid leukemia (CML). The exact mechanism of IGM remains controversial. Although a case report has shown a decrease in insulin secretion1 , our previous pilot data suggested development of insulin resistance as a possible mechanism.2 In this prospective study we aimed to confirm results from our pilot study using a larger cohort of CML patients treated with nilotinib and to compare results with data obtained on control groups receiving imatinib and dasatinib.

Links

NV17-30397A, research and development project

Name: Mutační analýza primitivních buněčných populací u chronické myeloidní leukémie: za hranicí BCR-ABL1

Citovat

RÁČIL, Zdeněk, Eva KORIŤÁKOVÁ, Tomasz SACHA, Hana KLAMOVA, Petra BELOHLAVKOVA, Edgar FABER, Delphine REA, Ludmila MALASKOVA, Jiřina PROCHÁZKOVÁ, Daniela ŽÁČKOVÁ, Jaroslava VOGLOVA, Joanna WACLAW, Petr CETKOVSKY, Pavel ZAK and Jiří MAYER. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. American Journal of Hematology. Hoboken: John Wiley & Sons, 2018, vol. 93, No 10, p. "E342"-"E345", 4 pp. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.25232.

@article{1478081,
   author = {Ráčil, Zdeněk and Koriťáková, Eva and Sacha, Tomasz and Klamova, Hana and Belohlavkova, Petra and Faber, Edgar and Rea, Delphine and Malaskova, Ludmila and Procházková, Jiřina and Žáčková, Daniela and Voglova, Jaroslava and Waclaw, Joanna and Cetkovsky, Petr and Zak, Pavel and Mayer, Jiří},
   article_location = {Hoboken},
   article_number = {10},
   doi = {http://dx.doi.org/10.1002/ajh.25232},
   keywords = {nilotinib therapy},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy},
   volume = {93},
   year = {2018}
}

TY  - JOUR
ID  - 1478081
AU  - Ráčil, Zdeněk - Koriťáková, Eva - Sacha, Tomasz - Klamova, Hana - Belohlavkova, Petra - Faber, Edgar - Rea, Delphine - Malaskova, Ludmila - Procházková, Jiřina - Žáčková, Daniela - Voglova, Jaroslava - Waclaw, Joanna - Cetkovsky, Petr - Zak, Pavel - Mayer, Jiří
PY  - 2018
TI  - Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy
JF  - American Journal of Hematology
VL  - 93
IS  - 10
SP  - "E342"-"E345"
EP  - "E342"-"E345"
PB  - John Wiley & Sons
SN  - 03618609
KW  - nilotinib therapy
N2  - Impaired glucose metabolism (IGM) with hyperglycemia represents one of the most frequently observed adverse events (AE) during nilotinib therapy of chronic myeloid leukemia (CML). The exact mechanism of IGM remains controversial. Although a case report has shown a decrease in insulin secretion1 , our previous pilot data suggested development of insulin resistance as a possible mechanism.2 In this prospective study we aimed to confirm results from our pilot study using a larger cohort of CML patients treated with nilotinib and to compare results with data obtained on control groups receiving imatinib and dasatinib.
ER  -

RÁČIL, Zdeněk, Eva KORIŤÁKOVÁ, Tomasz SACHA, Hana KLAMOVA, Petra BELOHLAVKOVA, Edgar FABER, Delphine REA, Ludmila MALASKOVA, Jiřina PROCHÁZKOVÁ, Daniela ŽÁČKOVÁ, Jaroslava VOGLOVA, Joanna WACLAW, Petr CETKOVSKY, Pavel ZAK and Jiří MAYER. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2018, vol.~93, No~10, p.~''E342''-''E345'', 4 pp. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.25232.

Detailed Information on Publication Record